The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Open accessAbstract
Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3–5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection followed by radiotherapy with concomitant and adjuvant therapies. Despite these aggressive therapeutic regimens, the majority of patients suffer recurrence due to molecular heterogeneity of GBM. Consequently, a number of potential diagnostic, prognostic, and predictive biomarkers have been investigated. Some of them, such as IDH mutations, 1p19q deletion, MGMT promoter methylation, and EGFRvIII amplification are frequently tested in routine clinical practice. With the development of sequencing technology, detailed characterization of GBM molecular signatures has facilitated a more personalized therapeutic approach and contributed to the development of a new generation of anti-GBM therapies such as molecular inhibitors targeting growth factor receptors, vaccines, antibody-based drug conjugates, and more recently inhibitors blocking the immune checkpoints. In this article, we review the exciting progress towards elucidating the potential of current and novel GBM biomarkers and discuss their implications for clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Bhat, K. P. L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J. D., Goodman, L. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.001 · Cited by 1,102
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
Choi, C., Ganji, S. K., DeBerardinis, R. J., Hatanpaa, K. J., Rakheja, D., Kovacs, Z., Yang, X.-L., Mashimo, T., Raisanen, J. M., Marin-Valencia, I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2682 · Cited by 839
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Huse, J. T., & Holland, E. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2818 · Cited by 763
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy
Shao, H., Chung, J., Balaj, L., Charest, A., Bigner, D. D., Carter, B. S., Hochberg, F. H., Breakefield, X. O., Weissleder, R., & Lee, H. (2012) · Nature Medicine · doi:10.1038/nm.2994 · Cited by 759
Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70314-6 · Cited by 759
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Mao, P., Joshi, K., Li, J., Kim, S.-H., Li, P., Santana-Santos, L., Luthra, S., Chandran, U. R., Benos, P. V., Smith, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221478110 · Cited by 642
Pauleit, D. (2005) · Brain · doi:10.1093/brain/awh399 · Cited by 634
PD-L1 expression and prognostic impact in glioblastoma
Nduom, E. K., Wei, J., Yaghi, N. K., Huang, N., Kong, L.-Y., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J. Q., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov172 · Cited by 596
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 585
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · cited 1×
“These proteins catalyze the oxidative carboxylation of isocitrate to alpha-ketoglutarate, which results in the production of NADPH in the citric acid (Krebs) cycle [64, 65].”
BackgroundOstrom, Q. T., de Blank, P. M., Kruchko, C., Petersen, C. M., Liao, P., Finlay, J. L., Stearns, D. S., Wolff, J. E., Wolinsky, Y., Letterio, J. J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou327 · Cited by 552
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
Diehn, M., Nardini, C., Wang, D. S., McGovern, S., Jayaraman, M., Liang, Y., Aldape, K., Cha, S., & Kuo, M. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801279105 · Cited by 440
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Barajas, R. F., Chang, J. S., Segal, M. R., Parsa, A. T., McDermott, M. W., Berger, M. S., & Cha, S. (2009) · Radiology · doi:10.1148/radiol.2532090007 · Cited by 407
Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E., & Ding, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404298200 · Cited by 403
Hu, L. S., Baxter, L. C., Smith, K. A., Feuerstein, B. G., Karis, J. P., Eschbacher, J. M., Coons, S. W., Nakaji, P., Yeh, R. F., Debbins, J., et al. (2009) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1377 · Cited by 396
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Furnari, F. B., Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3918 · Cited by 381
Emerging treatment strategies for glioblastoma multiforme
Carlsson, S. K., Brothers, S. P., & Wahlestedt, C. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201302627 · Cited by 365
Genetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355
Molecularly targeted therapy for malignant glioma
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N. (2007) · Cancer · doi:10.1002/cncr.22741 · Cited by 325
Weller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Pelloski, C. E., Ballman, K. V., Furth, A. F., Zhang, L., Lin, E., Sulman, E. P., Bhat, K., McDonald, J. M., Yung, W. K. A., Colman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0705 · Cited by 311
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 311
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Abounader, R., & Laterra, J. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000050 · Cited by 300
Pöpperl, G., Kreth, F. W., Mehrkens, J. H., Herms, J., Seelos, K., Koch, W., Gildehaus, F. J., Kretzschmar, H. A., Tonn, J. C., & Tatsch, K. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0534-y · Cited by 288
Chakrabarti, R., Hwang, J., Andres Blanco, M., Wei, Y., Lukačišin, M., Romano, R.-A., Smalley, K., Liu, S., Yang, Q., Ibrahim, T., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2607 · Cited by 285
Spence, A. M., Muzi, M., Swanson, K. R., O'Sullivan, F., Rockhill, J. K., Rajendran, J. G., Adamsen, T. C. H., Link, J. M., Swanson, P. E., Yagle, K. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4995 · Cited by 277
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J.-I. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 264
Prognostic significance of preoperative MRI scans in glioblastoma multiforme
Hammoud, M. A., Sawaya, R., Shi, W., Thall, P. F., & Leeds, N. E. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00146086 · Cited by 263
Paz, M. F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Aguirre-Cruz, L., García-Lopez, J. L., Piquer, J., Safont, M.-J., Balaña, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0392 · Cited by 261
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 252
Nakamura, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1715 · Cited by 248
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00005 · Cited by 245
Mabray, M. C., Barajas, R. F., & Cha, S. (2015) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2015.3.1.8 · Cited by 237
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., Sabel, M. C., Koeppen, S., Ketter, R., Weiler, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95680 · Cited by 234
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., & Yung, W. K. A. (1996) · PubMed · Cited by 228
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
Doucette, T., Rao, G., Rao, A., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M., & Heimberger, A. B. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0028 · Cited by 226
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222 · cited 1×
“IDH genes are present at the 132 residue in IDH1 (85%) and at 172 in IDH2 (3%) [12, 68].”
BackgroundFranceschi, E., Cavallo, G., Lonardi, S., Magrini, E., Tosoni, A., Grosso, D., Scopece, L., Blatt, V, Urbini, B., Pession, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603669 · Cited by 211
Weller, M., Stupp, R., Hegi, M. E., van den Bent, M., Tonn, J. C., Sanson, M., Wick, W., & Reifenberger, G. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos206 · Cited by 202
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Popovici-Muller, J., Saunders, J. O., Salituro, F. G., Travins, J. M., Yan, S., Zhao, F., Gross, S., Dang, L., Yen, K. E., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300225h · Cited by 200
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro, A. M. P., Faivre, S., & Raymond, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0047 · Cited by 196
Molecular and cellular heterogeneity: the hallmark of glioblastoma
Aum, D. J., Kim, D. H., Beaumont, T. L., Leuthardt, E. C., Dunn, G. P., & Kim, A. H. (2014) · Neurosurgical Focus · doi:10.3171/2014.9.focus14521 · Cited by 191
Glioma Stem Cells: Signaling, Microenvironment, and Therapy
Liebelt, B. D., Shingu, T., Zhou, X., Ren, J., Shin, S. A., & Hu, J. (2016) · Stem Cells International · doi:10.1155/2016/7849890 · Cited by 191
Molecular neuro-oncology in clinical practice: a new horizon
Weller, M., Pfister, S. M., Wick, W., Hegi, M. E., Reifenberger, G., & Stupp, R. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70168-2 · Cited by 189
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Promoter Hypermethylation of the RB1 Gene in Glioblastomas
Nakamura, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780213 · Cited by 184
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J.-T., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 176
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
Montano, N., Cenci, T., Martini, M., D’Alessandris, Q. G., Pelacchi, F., Ricci‐Vitiani, L., Maira, G., Maria, R. D., Larocca, L. M., & Pallini, R. (2011) · Neoplasia · doi:10.1593/neo.111338 · Cited by 169
11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET
Kim, S., Chung, J.-K., Im, S.-H., Jeong, J. M., Lee, D. S., Kim, D. G., Jung, H., & Lee, M. C. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1598-6 · Cited by 168
MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
Korfiatis, P., Kline, T. L., Coufalova, L., Lachance, D. H., Parney, I. F., Carter, R. E., Buckner, J. C., & Erickson, B. J. (2016) · Medical Physics · doi:10.1118/1.4948668 · Cited by 163
Pope, W. B., Qiao, X. J., Kim, H. J., Lai, A., Nghiemphu, P., Xue, X., Ellingson, B. M., Schiff, D., Aregawi, D., Cha, S., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0847-y · Cited by 160
Fueger, B. J., Czernin, J., Cloughesy, T., Silverman, D. H., Geist, C. L., Walter, M. A., Schiepers, C., Nghiemphu, P., Lai, A., Phelps, M. E., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.078592 · Cited by 159
Armstrong, T. S., Wefel, J. S., Wang, M., Gilbert, M. R., Won, M., Bottomley, A., Mendoza, T. R., Coens, C., Werner‐Wasik, M., Brachman, D. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6067 · Cited by 153
Cytotoxic T-Lymphocyte–Associated Antigen-4
Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 153
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 151
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Liu, Y., Carlsson, R., Ambjørn, M., Hasan, M., Badn, W., Darabi, A., Siesjö, P., & Issazadeh‐Navikas, S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5812-12.2013 · Cited by 151
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
Chen, J.-R., Yao, Y., Xu, H., & Qin, Z. (2016) · Medicine · doi:10.1097/md.0000000000002583 · Cited by 151
Fitz, C. D. V., Giacomini, C. P., Vogel, H. S., Jensen, K. C., Florio, T., Merlo, A., Pollack, J. R., & Wong, A. J. (2012) · Oncogene · doi:10.1038/onc.2012.280 · Cited by 150
Ellingson, B. M., Cloughesy, T. F., Pope, W. B., Zaw, T. M., PHILLIPS, H. S., Lalezari, S., Nghiemphu, P. L., Ibrahim, H., Naeini, K. M., Harris, R. J., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.076 · Cited by 148
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 141
Affronti, M. L., Heery, C. R., Herndon, J. E., Rich, J. N., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Friedman, A. H., Bigner, D. D., & Friedman, H. S. (2009) · Cancer · doi:10.1002/cncr.24398 · Cited by 138
Weller, M., Kaulich, K., Hentschel, B., Felsberg, J., Gramatzki, D., Pietsch, T., Simon, M., Westphal, M., Schackert, G., Tonn, J. C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28576 · Cited by 119
Larsen, V. A., Simonsen, H. J., Law, I. G., Larsson, H. B. W., & Hansen, A. E. (2012) · Neuroradiology · doi:10.1007/s00234-012-1127-4 · Cited by 112
Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study
Zawlik, I., Vaccarella, S., Kita, D., Mittelbronn, M. G. A., Franceschi, S., & Ohgaki, H. (2008) · Neuroepidemiology · doi:10.1159/000170088 · Cited by 111
Fong, B., Jin, R. M., Wang, X., Safaee, M., Lisiero, D. N., Yang, I., Li, G., Liau, L. M., & Prins, R. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032614 · Cited by 108
Stem cell signature in glioblastoma: therapeutic development for a moving target
Nakano, I. (2014) · Journal of neurosurgery · doi:10.3171/2014.9.jns132253 · Cited by 105
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 105
Wiestler, B., Claus, R., Hartlieb, S. A., Schliesser, M. G., Weiß, E. K., Hielscher, T., Platten, M., Dittmann, L. M., Meisner, C., Felsberg, J., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not043 · Cited by 94
Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Appin, C., & Brat, D. J. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000048 · Cited by 93
Current Vaccine Trials in Glioblastoma: A Review
Xu, L. W., Chow, K. K. H., Lim, M. K., & Li, G. (2014) · Journal of Immunology Research · doi:10.1155/2014/796856 · Cited by 87
Clinical impact of molecular biomarkers in gliomas
Siegal, T. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.004 · Cited by 87
The challenges associated with molecular targeted therapies for glioblastoma
Jue, T. R., & McDonald, K. L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2080-6 · Cited by 74
EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers
Faulkner, C., Palmer, A., Williams, H., Wragg, C., Haynes, H. R., White, P., deSouza, R., Williams, M., Hopkins, K., & Kurian, K. M. (2014) · British Journal of Neurosurgery · doi:10.3109/02688697.2014.950631 · Cited by 73
Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas
Hobbs, J. G., Nikiforova, M. N., Fardo, D. W., Bortoluzzi, S., Cieply, K. M., Hamilton, R. L., & Horbinski, C. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182518e12 · Cited by 71
Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma
Wu, C., Lin, G.-S., Lin, Z., ZHANG, J.-D., Chen, L., LIU, S.-Y., Tang, W., Qiu, X., & ZHOU, C.-F. (2015) · Oncology Letters · doi:10.3892/ol.2015.3639 · Cited by 71
Gupta, A. K., Young, R. J., Shah, A. D., Schweitzer, A. D., Graber, J. J., Shi, W., Zhang, Z., Huse, J. T., & Omuro, A. M. P. (2014) · Clinical Neuroradiology · doi:10.1007/s00062-014-0289-3 · Cited by 70
Ipilimumab and whole brain radiation therapy for melanoma brain metastases
Gerber, N. K., Young, R. J., Barker, C. A., Wolchok, J. D., Chan, T. A.-T., Yamada, Y. J., Friguglietti, L., & Beal, K. P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1617-9 · Cited by 69
The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma
Huse, J. T., & Aldape, K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0831 · Cited by 69
The assessment of prognostic factors in surgical treatment of low-grade gliomas: A prospective study
Majchrzak, K., Kaspera, W., Bobek‐Billewicz, B., Hebda, A., Stasik-Pres, G., Majchrzak, H., & Ładziński, P. (2012) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2012.02.054 · Cited by 65
Self-citationProgress in the application of molecular biomarkers in gliomas
Wang, J., Su, H.-K., Zhao, H., Chen, Z.-P., & To, S. S. T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.148 · Cited by 59
Advances in the treatment of newly diagnosed glioblastoma
Theeler, B. J., & Gilbert, M. R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0536-8 · Cited by 51
Young, R. J., Gupta, A. K., Shah, A. D., Graber, J. J., Schweitzer, A. D., Prager, A. J., Shi, W., Zhang, Z., Huse, J. T., & Omuro, A. M. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3604 · Cited by 44
Thuy, M. N. T., Kam, J. K. T., Lee, G. C. Y., Tao, P., Ling, D., Cheng, M., Goh, S. K., Papachristos, A., Shukla, L., Wall, K.-L., et al. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.029 · Cited by 41
AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma
Joy, A. M., Ramesh, A., Smirnov, I. V., Reiser, M., Misra, A., Shapiro, W. R., Mills, G. B., Kim, S., & Feuerstein, B. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100827 · Cited by 20
Reoperations of patients with low-grade gliomas in eloquent or near eloquent brain areas
Kaspera, W., Majchrzak, K., Bobek‐Billewicz, B., Hebda, A., Stasik-Pres, G., Majchrzak, H., Ładziński, P., & Machowska-Majchrzak, A. (2013) · Neurologia i Neurochirurgia Polska · doi:10.5114/ninp.2013.34399 · Cited by 16
Self-citationIsocitrate dehydrogenase mutations: new opportunities for translational research
Keum, Y., & Choi, B. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.021 · Cited by 11
Cited by
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Tan, S. K., Pastori, C., Penas, C., Komotar, R. J., Ivan, M. E., Wahlestedt, C., & Ayad, N. G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0822-0 · Cited by 271
Liquid biopsy: creating opportunities in brain space
Trivedi, R., & Bhat, K. P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02446-0 · Cited by 27
Metadata
- Authors
- Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-13
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2590936958
- Cited by
- 320
- References
- 136
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.